Growing community of inventors

Shanghai, China

Xianguo Zhao

Average Co-Inventor Count = 8.84

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Xianguo ZhaoXiangrui Jiang (2 patents)Xianguo ZhaoZheng Liu (1 patent)Xianguo ZhaoHualiang Jiang (1 patent)Xianguo ZhaoZhen Wang (1 patent)Xianguo ZhaoJingshan Shen (1 patent)Xianguo ZhaoGuan Zhong Wang (1 patent)Xianguo ZhaoJianfeng Li (1 patent)Xianguo ZhaoGuanghui Tian (1 patent)Xianguo ZhaoXiaojun Yang (1 patent)Xianguo ZhaoRongxia Zhang (1 patent)Xianguo ZhaoWeiming Chen (1 patent)Xianguo ZhaoFuqiang Zhu (1 patent)Xianguo ZhaoJin Suo (1 patent)Xianguo ZhaoWeiliang Zhu (1 patent)Xianguo ZhaoXudong Gong (1 patent)Xianguo ZhaoZhu Xie (1 patent)Xianguo ZhaoXianguo Zhao (2 patents)Xiangrui JiangXiangrui Jiang (7 patents)Zheng LiuZheng Liu (109 patents)Hualiang JiangHualiang Jiang (42 patents)Zhen WangZhen Wang (30 patents)Jingshan ShenJingshan Shen (18 patents)Guan Zhong WangGuan Zhong Wang (16 patents)Jianfeng LiJianfeng Li (12 patents)Guanghui TianGuanghui Tian (12 patents)Xiaojun YangXiaojun Yang (9 patents)Rongxia ZhangRongxia Zhang (9 patents)Weiming ChenWeiming Chen (6 patents)Fuqiang ZhuFuqiang Zhu (4 patents)Jin SuoJin Suo (3 patents)Weiliang ZhuWeiliang Zhu (3 patents)Xudong GongXudong Gong (2 patents)Zhu XieZhu Xie (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Chinese Academy of Sciences (2 from 3,107 patents)

2. Topharman Shanghai Co., Ltd. (2 from 15 patents)

3. Topharman Shandong Co., Ltd. (1 from 4 patents)


2 patents:

1. 9527849 - Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof

2. 9376410 - (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/8/2026
Loading…